Stem Cell Therapeutics Corp. Announces Presentation by Dr. Joshua M. Hare on NTx-265(R) Animal Data After

CALGARY, ALBERTA, Mar 30 (MARKET WIRE) --
Stem Cell Therapeutics Corp. (the "Company" or "SCT") (TSX VENTURE: SSS)
announced today that Dr. Joshua M. Hare, MD, FACC, Louis Lemberg
Professor of Medicine and Director, Interdisciplinary Stem Cell Institute
(ISCI) at the University of Miami, presented the "Effects of Combination
of Proliferative Agents and Erythropoeitin (EPO) on Left Ventricular
Remodeling Post-Myocardial Infarction" at the 58th Annual American
College of Cardiology Conference in Orlando, Florida.

The study, conducted by Dr. Hare's team at the University of Miami,
described the effects of two drug regimens: human Chorionic Gonadotropin
(hCG) plus EPO (NTx-265(R) regimen) and a regimen composed of prolactin
(PRL) then EPO. Both of the regimens were dosed in a similar manner,
following a severe left ventricular coronary occlusion - heart attack -
in rats.

The study demonstrated that after a severe myocardial infarction (MI),
the left ventricle chamber dimension increased by approximately 200% and
decreased in ejection fraction by about 44%. Systemic treatment with hCG,
EPO or hCG plus EPO (NTx-265(R) regimen) significantly limited the
expansion of ventricular chamber dimension and reversed the effects on
ejection fraction by approximately 50%. Prolactin, however, did not have
this effect.

Dr. Hare concluded "that hCG alone or in combination with EPO may be an
effective therapeutic strategy to ameliorate post-MI remodeling. The
absence of this same effect with PRL suggests a direct effect of on
NTx-265(R) on the myocardium." Moreover, Dr. Hare also believes that
"given the established safety profile of hCG in humans, clinical trials
may be warranted as a next step."

Dr. Alan Moore, President and CEO, commented as follows:

"This recently completed study by Dr. Hare builds upon earlier
observations that NTx-265(R) modulates the activity of a population of
cells within the adult heart. We are pleased to now have the confirmation
of a long suspected positive effect on recovery following heart attack.
The exciting, novel study results suggest that an entirely new
therapeutic drug approach may be possible in the heart and emphasizes the
enormous potential that is captured within SCT's patent portfolio."

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a
Canadian public biotechnology company (TSX VENTURE: SSS) focused on the
development and commercialization of drug-based therapies to treat
central nervous system diseases. SCT is a leader in the development of
therapies that utilize drugs to stimulate a patient's own resident stem
cells. The Company's programs aim to repair neurological function lost
due to disease or injury. SCT's extensive patent portfolio of owned and
licensed intellectual property supports the potential expansion into
future clinical programs in numerous neurological diseases such as
traumatic brain injury, multiple sclerosis, Huntington's disease,
Alzheimer's disease, and ALS.

For further information on Stem Cell Therapeutics Corp., visit
www.stemcellthera.com.

These securities have not been registered under the United States
Securities Act of 1933, as amended, or the securities laws of any state,
and may not be offered or sold within the United States or to, or for the
account or benefit of U.S. persons unless an applicable exemption from
U.S. registration requirements is available.

Except for historical information, this press release may contain
forward-looking statements, which reflect the Company's current
expectation regarding future events. These forward-looking statements
involve risk and uncertainties, which may cause but are not limited to,
changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact of
competitive products and pricing, new product development, uncertainties
related to the regulatory approval process and other risks detailed from
time to time in the Company's ongoing quarterly and annual reporting.

Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.

Contacts:
Stem Cell Therapeutics Corp.
Alan Moore, PhD
President and CEO
(403) 245-5495 ext.224
Email: amoore@stemcellthera.com

Stem Cell Therapeutics Corp.
Chloe Douglas-Crampton
Investor Relations
(403) 245-5495 ext. 221
Email: crampton@stemcellthera.com
Website: www.stemcellthera.com

Copyright 2009, Market Wire, All rights reserved.

-0-